Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Puris, Elena [VerfasserIn]   i
 Petralla, Sabrina [VerfasserIn]   i
 Auriola, Seppo [VerfasserIn]   i
 Kidron, Heidi [VerfasserIn]   i
 Fricker, Gert [VerfasserIn]   i
 Gynther, Mikko [VerfasserIn]   i
Titel:Monoacylglycerol lipase inhibitor JJKK048 ameliorates ABCG2 transporter-mediated regorafenib resistance induced by hypoxia in triple negative breast cancer cells
Verf.angabe:Elena Puris, Sabrina Petralla, Seppo Auriola, Heidi Kidron, Gert Fricker, Mikko Gynther
E-Jahr:2023
Jahr:15 August 2023
Umfang:10 S.
Fussnoten:Online verfügbar 21 May 2023, Version des Artikels 15 August 2023 ; Gesehen am 16.10.2023
Titel Quelle:Enthalten in: Journal of pharmaceutical sciences
Ort Quelle:Amsterdam : Elsevier, 1911
Jahr Quelle:2023
Band/Heft Quelle:112(2023), 9 vom: Sept., Seite 2581-2590
ISSN Quelle:1520-6017
Abstract:Triple negative breast cancer (TNBC) is among the most aggressive and deadly cancer subtypes. Intra-tumoral hypoxia is associated with aggressiveness and drug resistance in TNBC. One of the underlying mechanisms of hypoxia-induced drug resistance is the elevated expression of efflux transporters such as breast cancer resistant protein (ABCG2). In the present study, we investigated the possibility of ameliorating ABCG2-mediated drug resistance in hypoxic TNBC cells by monoacylglycerol lipase (MAGL) inhibition and the consequent downregulation of ABCG2 expression. The effect of MAGL inhibition on ABCG2 expression, function, and efficacy of regorafenib, an ABCG2 substrate was investigated in cobalt dichloride (CoCl2) induced pseudohypoxic TNBC (MDA-MB-231) cells, using quantitative targeted absolute proteomics, qRT-PCR, anti-cancer drug accumulation in the cells, cell invasiveness and resazurin-based cell viability assays. Our results showed that hypoxia-induced ABCG2 expression led to low regorafenib intracellular concentrations, reduced the anti-invasiveness efficacy, and elevated half maximal inhibitory concentration (IC50) of regorafenib in vitro MDA-MB-231 cells. MAGL inhibitor, JJKK048, reduced ABCG2 expression, increased regorafenib cell accumulation, which led to higher regorafenib efficacy. In conclusion, hypoxia-induced regorafenib resistance due to ABCG2 over-expression in TNBC cells can be ameliorated by MAGL inhibition.
DOI:doi:10.1016/j.xphs.2023.05.012
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1016/j.xphs.2023.05.012
 Volltext: https://www.sciencedirect.com/science/article/pii/S0022354923001983
 DOI: https://doi.org/10.1016/j.xphs.2023.05.012
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Anti-cancer drug resistance
 Breast cancer resistance protein
 Hypoxia
 Monoacylglycerol lipase
 Triple negative breast cancer
K10plus-PPN:1865711438
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69129822   QR-Code
zum Seitenanfang